Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH collaboration

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Nov 17, 2021 11:08am

104 Views

Post# 34136209

RE:RE:NASH collaboration

It was part of this deal. It's one of the 3 additional targets thrown in. I think if TH makes partnership deals with the Sortilin platform it could be structured similarly. The broad applications of the program will require companies to explore all kinds of chemo drugs linked to the peptide in many types of cancers.

https://www.businesswire.com/news/home/20181004005195/en/Arrowhead-Enters-3.7-Billion-License-and-Collaboration-Agreements-with-Janssen

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland